PF-06473871 + PF-06473871

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Reduction of Hypertrophic Skin Scarring

Conditions

Reduction of Hypertrophic Skin Scarring

Trial Timeline

Dec 1, 2012 → Oct 1, 2014

NCT ID

NCT01730339

About PF-06473871 + PF-06473871

PF-06473871 + PF-06473871 is a phase 2 stage product being developed by Pfizer for Reduction of Hypertrophic Skin Scarring. The current trial status is completed. This product is registered under clinical trial identifier NCT01730339. Target conditions include Reduction of Hypertrophic Skin Scarring.

What happened to similar drugs?

2 of 2 similar drugs in Reduction of Hypertrophic Skin Scarring were approved

Approved (2) Terminated (1) Active (0)

✅Biktarvy 50Mg-200Mg-25Mg TabletGilead SciencesApproved

✅1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Omeros CorporationApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02205476	Phase 2	Terminated	Dec 1, 2014	Jan 1, 2015	Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
NCT01730339	Phase 2	Completed	Dec 1, 2012	Oct 1, 2014	Reduction of Hypertrophic Skin Scarring

Competing Products

4 competing products in Reduction of Hypertrophic Skin Scarring

See all competitors

Product	Company	Stage	Hype Score
Biktarvy 50Mg-200Mg-25Mg Tablet	Gilead Sciences	Approved	43
EXC 001 (currently called PF-06473871)	Pfizer	Phase 2	35
EXC 001 + EXC 001 + EXC 001 + EXC 001	Pfizer	Phase 2	35
1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%	Omeros Corporation	Approved	29